article thumbnail

Overcoming Barriers to Generative AI in Life Sciences R&D

Fierce BioTech

| While artificial intelligence is on everyone’s minds and in many R&D plans, adoption of generative AI has been slow so far in life sciences.

Science 118
article thumbnail

Pioneer Group’s life sciences campuses host biggest Ada Lovelace Day event to date

Drug Discovery Today

Pioneer Group, the specialist life science infrastructure and venture-building company, welcomed 425 school children from 29 schools to eight of its sites across the UK last week to mark Ada Lovelace Day, an international celebration of the achievements of women in STEM.

Science 113
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Science Reveals Why Cancer Immunotherapies Can Sometimes Harm the Heart

Drugs.com

FRIDAY, Nov. 8, 2024 -- Researchers think they’ve figured out why cancer treatments that harness a person’s immune system to fight a tumor can cause heart damage in rare instances.Further, what they’ve learned sheds light on how this potentially dea.

Science 116
article thumbnail

Arch raises another $3B biotech fund in pursuit of ‘coolest’ new science

BioPharma Drive: Drug Pricing

Despite working in a restrictive funding climate, the prolific startup creator is “in the ‘taking lots of risk’ mode,” said co-founder and managing director Robert Nelsen.

Science 124
article thumbnail

Boost Alphafold2 Protein Structure Prediction with GPU-Accelerated MMseqs2

Nvidia Developer: Drug Discovery

The ability to compare the sequences of multiple related proteins is a foundational task for many life science researchers. The ability to compare the sequences of multiple related proteins is a foundational task for many life science researchers. This is often done in the form of a.

Science 124
article thumbnail

An Alzheimer’s drugmaker is accused of data manipulation. Should its trials be stopped?

BioPharma Drive: Drug Pricing

An experimental Alzheimer’s therapy from Cassava Sciences is still being tested in two Phase 3 studies, even as the company has come under regulatory scrutiny.

Trials 144
article thumbnail

RNA editing: emerging from CRISPR’s shadow

BioPharma Drive: Drug Pricing

Early study data from Wave Life Sciences suggests how editing RNA may yield viable medicines. Large and small drugmakers say such results are just the start.

RNA 141